You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury Resuscitation

    SBC: SYNZYME TECHNOLOGIES LLC            Topic: 102

    DESCRIPTION provided by applicant Traumatic brain injury TBI is a leading cause of morbidity and mortality especially when complicated by secondary insults such as hypotension Vulnerability of TBI patients to hypotension is well recognized and identifies a key need for new approaches The goal of this proposal is to develop to IND a neuroprotective hyper colloid oxygen therapeutic polynit ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid, Near-Tranfusion Test for Bacteria in Platelets Units

    SBC: IMMUNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Bacterial contamination of platelets is considered the greatest infectious risk of blood product transfusion today at about in platelet units which is several orders of magnitude greater than that of HIV Bacterial contamination at high levels can lead to severe morbidity or mortality in transfusion recipients The American Association of Blood Banks is ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A high resolution and high DQE detector optimized for mammography using single shot bi directional tri contrast imaging

    SBC: Sigray, Inc.            Topic: NIBIB

    DESCRIPTION provided by applicant X ray tricontrast imaging provides three different modes of contrast absorption contrast the mechanism behind how conventional medical X ray imaging equipment images phase contrast which provides up to X more contrast than absorption based contrast for soft tissue and scatter contrast which provides information of features at dimensions smaller than ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Mycotoxin Neutralization Treatment

    SBC: Physical Optics Corporation            Topic: CBD152003

    To address the Chemical and Biological Defense programs (CBDs) need for medical countermeasures against mycotoxin intoxication, PhysicalOptics Corporation (POC) proposes to develop a new Mycotoxin Neutralization Treatment (MyNT). This proposed solution is based on neutralizingmycotoxin from its deleterious effects by acting on multiple levels of mycotoxin metabolism through the novel combination o ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  5. Exploiting Natural Products-Based Therapeutics for Aflatoxin Mitigation

    SBC: CFD Research Corporation            Topic: CBD152003

    Aflatoxins are a paradigm among fungal produced mycotoxins that are present in food supplies and are strongly associated with increased risk forthe development of hepatocellular carcinoma. Currently, there are no known countermeasures that can selectively mitigate aflatoxin toxicity andthe available options are only symptomatic treatments. To meet this challenge, we propose to harness the microbio ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  6. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors

    SBC: Neonc Technologies, Inc.            Topic: BT

    DESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment

    SBC: BIOVINC, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A method for accurate and sensitive detection of HIV drug-resistant minority variants

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. An epitope focused nanoparticle vaccine for MRSA and biodefense

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government